New LEADER Analysis Shows Victoza® Reduces Cardiovascular Risk in People With Type 2 Diabetes Regardless of Severe Hypoglycaemia Events
Bagsværd, Denmark (ots/PRNewswire) - Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk, regardless of whether ...